Pricing Log in Create free account
Friday 6 November 2026 Export CGON’s income statement to Excel — free account

CG Oncology, Inc.

CGON Healthcare Biotechnology

CG Oncology, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $4.0 million, up 254.7% from fiscal 2024.

Revenue
−3.72%
EPS
−12.3%
Free cash flow
−25.2%
Total debt
0.00%

Quarter to September 2026, against a year earlier

76.08 11.28 +17.41%
Market cap
$5.7B
P/E
0.0×
Fwd P/E
−19.5×
Dividend yield
—
F-score
2/9
Altman Z
49.04
Beneish M
n/a
Dividend safety
n/a
Overview
Financials
Income Statement Balance Sheet Cash Flow Metrics & Ratios

CG Oncology, Inc. (CGON) Current ratio

Alert me on Current ratio

CG Oncology, Inc.'s current ratio at the end of the quarter to 30 September 2026 was 21.7×, down 2.9× from fiscal 2025 (24.6×). That is above the Biotechnology industry median of 4.9× and above the Healthcare sector median of 3.1×.

Current ratio, annual

Embed this chart

Annual newest first

Period Current ratio Change
FY2025 24.6× (30.22%)
FY2024 35.3× 159.17%
FY2023 13.6× 42.74%
FY2022 9.5× —

Quarterly newest first

Period Current ratio Change
Sep 2026 21.7× (2.32%)
Jun 2026 22.2× (29.00%)
Mar 2026 31.3× 27.07%
Dec 2025 24.6× 8.06%
9 more quarters

Current ratio against peers

Company Current ratio
MANE Veradermics Incorporated compare 70.5×
BLTE Belite Bio, Inc. Sponsored ADR compare 33.6×
CGON CG Oncology, Inc. 22.2×
IMVT Immunovant, Inc. compare 7.3×
SRRK Scholar Rock Holding Corporation compare 7.0×
PTCT PTC Therapeutics, Inc. compare 3.3×
KOD Kodiak Sciences Inc. compare 2.5×
MIRM Mirum Pharmaceuticals, Inc. compare 2.1×
LGND Ligand Pharmaceuticals Incorporated compare 1.2×
Biotechnology industry median 4.9×
Healthcare sector median 3.1×
Market median 1.6×

What Current ratio is

Current Ratio shows whether a company’s short-term assets are enough to cover the bills and debts it must pay within the next year.

Current Assets (Total) ÷ Current Liabilities (Total)

The full definition of Current ratio →

More on CGON